Monoclonal Antibodies Against Epidermal Growth Factor Receptor in Advanced Colorectal Carcinoma: Clinical Efficacy and Markers of Sensitivity#

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|1|2|113-118

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.1, Iss.2, 2006-05, pp. : 113-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 3, Iss. 3, 2008-09 ,pp. : 217-227

Bentham Science Publishers

Access to resources Recommend Favorite

Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 1, 2008-11 ,pp. : 42-48

Karger

Access to resources Recommend Favorite

Clinical Significance of Insulin-Like Growth Factor Type 1 Receptor and Epidermal Growth Factor Receptor in Patients with Advanced Gastric Cancer

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 76-83

Karger

Access to resources Recommend Favorite

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3212-3220

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite